Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q4 FY21 results · Jan–Mar 2021
Sun Pharma Advanced Research Company reported revenue from operations of ₹28.06 crore (up 23.6% from Q4 FY20) and net loss of ₹56.72 crore for Q4 FY21 (Jan–Mar 2021), on a standalone basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 28.06 | 22.71 | +23.6% | 21.81 | +28.7% |
| Other income | 0.33 | 3.12 | −89.4% | 1.60 | −79.4% |
| Total income | 28.39 | 25.83 | +9.9% | 23.41 | +21.3% |
| Profit before tax | (56.72) | (99.54) | Loss narrowed | (67.62) | Loss narrowed |
| Net profit for the period | (56.72) | (99.54) | Loss narrowed | (67.62) | Loss narrowed |
| EPS, basic (₹) | (2.16) | (3.80) | Loss narrowed | (2.58) | Loss narrowed |
| Net margin (%) | -202.1 | -438.3 | -310.0 |
Standalone
- Filed with BSE
- 18 May 2021, 18:59 IST
- Board meeting
- 17 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE